Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Tumour-agnostic drugs and future cancer treatment.

Børset M.

Tidsskr Nor Laegeforen. 2019 Mar 11;139(5). doi: 10.4045/tidsskr.19.0005. Print 2019 Mar 12. Norwegian, English. No abstract available.

2.

Correction: MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy.

Holien T, Misund K, Olsen OE, Baranowska KA, Buene G, Børset M, Waage A, Sundan A.

Oncotarget. 2018 Nov 13;9(89):36048. doi: 10.18632/oncotarget.26373. eCollection 2018 Nov 13.

3.

PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients.

Sponaas AM, Yang R, Rustad EH, Standal T, Thoresen AS, Dao Vo C, Waage A, Slørdahl TS, Børset M, Sundan A.

Oncotarget. 2018 Aug 10;9(62):32024-32035. doi: 10.18632/oncotarget.25882. eCollection 2018 Aug 10.

4.

Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical Hodgkin lymphoma and promotes survival and migration.

Hjort MA, Hov H, Abdollahi P, Vandsemb EN, Fagerli UM, Lund B, Slørdahl TS, Børset M, Rø TB.

Exp Hematol Oncol. 2018 Apr 10;7:8. doi: 10.1186/s40164-018-0100-2. eCollection 2018.

5.
6.

Phosphatase of regenerating liver-3 is expressed in acute lymphoblastic leukemia and mediates leukemic cell adhesion, migration and drug resistance.

Hjort MA, Abdollahi P, Vandsemb EN, Fenstad MH, Lund B, Slørdahl TS, Børset M, Rø TB.

Oncotarget. 2017 Dec 13;9(3):3549-3561. doi: 10.18632/oncotarget.23186. eCollection 2018 Jan 9.

7.

Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.

Andersen S, Richardsen E, Rakaee M, Bertilsson H, Bremnes R, Børset M, Busund LT, Slørdahl T.

PLoS One. 2017 Nov 30;12(11):e0189000. doi: 10.1371/journal.pone.0189000. eCollection 2017.

8.

Monitoring multiple myeloma by quantification of recurrent mutations in serum.

Rustad EH, Coward E, Skytøen ER, Misund K, Holien T, Standal T, Børset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A.

Haematologica. 2017 Jul;102(7):1266-1272. doi: 10.3324/haematol.2016.160564. Epub 2017 Apr 6.

9.

Src Family Kinases Are Regulated in Multiple Myeloma Cells by Phosphatase of Regenerating Liver-3.

Abdollahi P, Vandsemb EN, Hjort MA, Misund K, Holien T, Sponaas AM, Rø TB, Slørdahl TS, Børset M.

Mol Cancer Res. 2017 Jan;15(1):69-77. doi: 10.1158/1541-7786.MCR-16-0212. Epub 2016 Oct 3.

10.

Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro.

Våtsveen TK, Sponaas AM, Tian E, Zhang Q, Misund K, Sundan A, Børset M, Waage A, Brede G.

J Hematol Oncol. 2016 Aug 31;9(1):75. doi: 10.1186/s13045-016-0306-x.

11.

VOLIN and KJON-Two novel hyperdiploid myeloma cell lines.

Våtsveen TK, Børset M, Dikic A, Tian E, Micci F, Lid AH, Meza-Zepeda LA, Coward E, Waage A, Sundan A, Kuehl WM, Holien T.

Genes Chromosomes Cancer. 2016 Nov;55(11):890-901. doi: 10.1002/gcc.22388. Epub 2016 Jul 12.

PMID:
27311012
12.

The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells.

Slørdahl TS, Abdollahi P, Vandsemb EN, Rampa C, Misund K, Baranowska KA, Westhrin M, Waage A, Rø TB, Børset M.

Oncotarget. 2016 May 10;7(19):27295-306. doi: 10.18632/oncotarget.8422.

13.

Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.

Vandsemb EN, Bertilsson H, Abdollahi P, Størkersen Ø, Våtsveen TK, Rye MB, Rø TB, Børset M, Slørdahl TS.

J Transl Med. 2016 Mar 15;14:71. doi: 10.1186/s12967-016-0830-z.

14.

Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression.

Tian E, Børset M, Sawyer JR, Brede G, Våtsveen TK, Hov H, Waage A, Barlogie B, Shaughnessy JD Jr, Epstein J, Sundan A.

Genes Chromosomes Cancer. 2015 Nov;54(11):692-701. doi: 10.1002/gcc.22280. Epub 2015 Jul 29.

15.

MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy.

Holien T, Misund K, Olsen OE, Baranowska KA, Buene G, Børset M, Waage A, Sundan A.

Oncotarget. 2015 Sep 8;6(26):22698-705. Erratum in: Oncotarget. 2018 Nov 13;9(89):36048.

16.

Activated CD8+ T cells and natural killer T cells in bronchoalveolar lavage fluid in hypersensitivity pneumonitis and sarcoidosis.

Tøndell A, Rø AD, Børset M, Moen T, Sue-Chu M.

Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jan 5;31(4):316-24.

PMID:
25591143
17.

Bronchoalveolar lavage fluid IFN-γ+ Th17 cells and regulatory T cells in pulmonary sarcoidosis.

Tøndell A, Moen T, Børset M, Salvesen Ø, Rø AD, Sue-Chu M.

Mediators Inflamm. 2014;2014:438070. doi: 10.1155/2014/438070. Epub 2014 May 5.

18.

Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients.

Rampa C, Tian E, Våtsveen TK, Buene G, Slørdahl TS, Børset M, Waage A, Sundan A.

Biomark Res. 2014 Apr 9;2(1):8. doi: 10.1186/2050-7771-2-8.

19.

Activated CD8(+) T cells and NKT cells in BAL fluid improve diagnostic accuracy in sarcoidosis.

Tøndell A, Rø AD, Åsberg A, Børset M, Moen T, Sue-Chu M.

Lung. 2014 Feb;192(1):133-40. doi: 10.1007/s00408-013-9527-8. Epub 2013 Nov 10.

PMID:
24213536
20.

Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.

Slørdahl TS, Denayer T, Moen SH, Standal T, Børset M, Ververken C, Rø TB.

Eur J Haematol. 2013 Nov;91(5):399-410. doi: 10.1111/ejh.12185. Epub 2013 Sep 16.

PMID:
23952536
21.

Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration.

Kristensen IB, Pedersen L, Rø TB, Christensen JH, Lyng MB, Rasmussen LM, Ditzel HJ, Børset M, Abildgaard N.

Eur J Haematol. 2013 Sep;91(3):196-200. doi: 10.1111/ejh.12125. Epub 2013 Jul 7.

PMID:
23607294
22.

HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase.

Rø TB, Holien T, Fagerli UM, Hov H, Misund K, Waage A, Sundan A, Holt RU, Børset M.

Exp Hematol. 2013 Jul;41(7):646-55. doi: 10.1016/j.exphem.2013.03.002. Epub 2013 Mar 14.

PMID:
23499762
23.

A method for measurement of drug sensitivity of myeloma cells co-cultured with bone marrow stromal cells.

Misund K, Baranowska KA, Holien T, Rampa C, Klein DC, Børset M, Waage A, Sundan A.

J Biomol Screen. 2013 Jul;18(6):637-46. doi: 10.1177/1087057113478168. Epub 2013 Feb 27.

PMID:
23446700
24.

Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease.

Wader KF, Fagerli UM, Børset M, Lydersen S, Hov H, Sundan A, Bofin A, Waage A.

Histopathology. 2012 Feb;60(3):443-51. doi: 10.1111/j.1365-2559.2011.04112.x.

PMID:
22276607
25.

Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC.

Holien T, Våtsveen TK, Hella H, Rampa C, Brede G, Grøseth LA, Rekvig M, Børset M, Standal T, Waage A, Sundan A.

Leukemia. 2012 May;26(5):1073-80. doi: 10.1038/leu.2011.263. Epub 2011 Sep 23. Erratum in: Leukemia. 2012 May;26(5):1154.

PMID:
21941367
26.

Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.

Fagerli UM, Ullrich K, Stühmer T, Holien T, Köchert K, Holt RU, Bruland O, Chatterjee M, Nogai H, Lenz G, Shaughnessy JD Jr, Mathas S, Sundan A, Bargou RC, Dörken B, Børset M, Janz M.

Oncogene. 2011 Jul 14;30(28):3198-206. doi: 10.1038/onc.2011.79. Epub 2011 Apr 11.

PMID:
21478911
27.

Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters.

Wader KF, Fagerli UM, Holt RU, Børset M, Sundan A, Waage A.

Eur J Haematol. 2011 Nov;87(5):394-9. doi: 10.1111/j.1600-0609.2011.01622.x. Epub 2011 Aug 16.

PMID:
21466586
28.

Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma.

Skliris A, Happonen KE, Terpos E, Labropoulou V, Børset M, Heinegård D, Blom AM, Theocharis AD.

Eur J Immunol. 2011 Feb;41(2):437-49. doi: 10.1002/eji.201040429. Epub 2010 Dec 30.

29.

[Immunization in pregnancy].

Heier HE, Berge LN, Hervig T, Kiserud T, Børset M, Eik-Nes S, Arsenovic M, Acharya G.

Tidsskr Nor Laegeforen. 2009 Oct 8;129(19):2016-8. doi: 10.4045/tidsskr.09.0186. Norwegian. No abstract available.

30.

FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14).

Våtsveen TK, Brenne AT, Dai HY, Waage A, Sundan A, Børset M.

Eur J Haematol. 2009 Nov;83(5):471-6. doi: 10.1111/j.1600-0609.2009.01312.x. Epub 2009 Jul 6.

PMID:
19594619
31.

OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus.

Våtsveen TK, Tian E, Kresse SH, Meza-Zepeda LA, Gabrea A, Glebov O, Dai HY, Sundan A, Kuehl WM, Børset M.

Leuk Res. 2009 Dec;33(12):1670-7. doi: 10.1016/j.leukres.2009.03.001. Epub 2009 Apr 23.

PMID:
19395026
32.

High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis.

Brenne AT, Fagerli UM, Shaughnessy JD Jr, Våtsveen TK, Rø TB, Hella H, Zhan F, Barlogie B, Sundan A, Børset M, Waage A.

Eur J Haematol. 2009 May;82(5):354-63. doi: 10.1111/j.1600-0609.2009.01225.x. Epub 2009 Jan 13.

33.

c-Met signaling promotes IL-6-induced myeloma cell proliferation.

Hov H, Tian E, Holien T, Holt RU, Våtsveen TK, Fagerli UM, Waage A, Børset M, Sundan A.

Eur J Haematol. 2009 Apr;82(4):277-87. doi: 10.1111/j.1600-0609.2009.01212.x. Epub 2009 Jan 6.

34.

Mn2+ regulates myeloma cell adhesion differently than the proadhesive cytokines HGF, IGF-1, and SDF-1alpha.

Slørdahl TS, Hov H, Holt RU, Baykov V, Syversen T, Sundan A, Waage A, Børset M.

Eur J Haematol. 2008 Dec;81(6):437-47. doi: 10.1111/j.1600-0609.2008.01148.x. Epub 2008 Sep 4.

PMID:
18774952
35.

Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma.

Wader KF, Fagerli UM, Holt RU, Stordal B, Børset M, Sundan A, Waage A.

Eur J Haematol. 2008 Nov;81(5):380-3. doi: 10.1111/j.1600-0609.2008.01130.x. Epub 2008 Aug 6.

36.

Hepatocyte growth factor promotes migration of human myeloma cells.

Holt RU, Fagerli UM, Baykov V, Rø TB, Hov H, Waage A, Sundan A, Børset M.

Haematologica. 2008 Apr;93(4):619-22. doi: 10.3324/haematol.11867. Epub 2008 Mar 6.

37.

Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.

Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B, Waage A, Aarset H, Dai HY, Shaughnessy JD Jr, Sundan A, Børset M.

Blood. 2008 Jan 15;111(2):806-15. Epub 2007 Oct 12.

38.

Bone disease in multiple myeloma.

Hjertner Ø, Standal T, Børset M, Sundan A, Waage A.

Med Oncol. 2006;23(4):431-41. Review.

PMID:
17303901
39.

HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma.

Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, Borset M, Sundan A.

Blood. 2007 Apr 1;109(7):3024-30.

PMID:
17138824
40.

Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro.

Theocharis AD, Seidel C, Borset M, Dobra K, Baykov V, Labropoulou V, Kanakis I, Dalas E, Karamanos NK, Sundan A, Hjerpe A.

J Biol Chem. 2006 Nov 17;281(46):35116-28. Epub 2006 Jul 26.

41.

Toll-like receptors mediate proliferation and survival of multiple myeloma cells.

Bohnhorst J, Rasmussen T, Moen SH, Fløttum M, Knudsen L, Børset M, Espevik T, Sundan A.

Leukemia. 2006 Jun;20(6):1138-44.

PMID:
16617319
42.

Skeletal tissue remodeling in multiple myeloma.

Borset M.

Haematologica. 2006 Feb;91(2):147b. No abstract available.

PMID:
16461293
43.

Identification of new targets for therapy of osteolytic bone disease in multiple myeloma.

Hjertner Ø, Standal T, Børset M, Sundan A, Waage A.

Curr Drug Targets. 2005 Sep;6(6):701-11. Review.

PMID:
16178802
44.

Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor.

Holt RU, Baykov V, Rø TB, Brabrand S, Waage A, Sundan A, Børset M.

Haematologica. 2005 Apr;90(4):479-88.

45.

Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.

Andersen NF, Standal T, Nielsen JL, Heickendorff L, Borset M, Sørensen FB, Abildgaard N.

Br J Haematol. 2005 Jan;128(2):210-7.

PMID:
15638855
46.

Role of osteopontin in adhesion, migration, cell survival and bone remodeling.

Standal T, Borset M, Sundan A.

Exp Oncol. 2004 Sep;26(3):179-84.

PMID:
15494684
47.

A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.

Hov H, Holt RU, Rø TB, Fagerli UM, Hjorth-Hansen H, Baykov V, Christensen JG, Waage A, Sundan A, Børset M.

Clin Cancer Res. 2004 Oct 1;10(19):6686-94.

48.

A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma.

Brenne AT, Romstad LH, Gimsing P, Juliusson G, Turesson I, Romundstad P, Borset M, Sundan A, Waage A.

Haematologica. 2004 May;89(5):552-6.

49.

Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.

Standal T, Hjorth-Hansen H, Rasmussen T, Dahl IM, Lenhoff S, Brenne AT, Seidel C, Baykov V, Waage A, Børset M, Sundan A, Hjertner O.

Haematologica. 2004 Feb;89(2):174-82.

50.

Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells.

Ro TB, Holt RU, Brenne AT, Hjorth-Hansen H, Waage A, Hjertner O, Sundan A, Borset M.

Oncogene. 2004 Apr 15;23(17):3024-32.

PMID:
14691444

Supplemental Content

Loading ...
Support Center